Skip to Content

SPDR® S&P Biotech ETF XBI

Medalist Rating as of | See State Street Investment Hub

Morningstar’s Analysis XBI

Will XBI outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

SPDR ® S&P Biotech ETF’s Process Pillar rating is Average, but a strong management team still helps this strategy retain its Morningstar Medalist Rating of Bronze.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a cost advantage over competitors, priced within the cheapest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings XBI

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 16.0
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Novavax Inc

3.10 207.5 Mil
Healthcare

Insmed Inc

2.15 144.1 Mil
Healthcare

Moderna Inc

1.61 107.4 Mil
Healthcare

Natera Inc

1.38 92.3 Mil
Healthcare

Revolution Medicines Inc Ordinary Shares

1.31 87.5 Mil
Healthcare

Dyne Therapeutics Inc Ordinary Shares

1.31 87.4 Mil
Healthcare

PTC Therapeutics Inc

1.26 84.1 Mil
Healthcare

United Therapeutics Corp

1.23 82.4 Mil
Healthcare

Blueprint Medicines Corp

1.22 81.5 Mil
Healthcare

Crinetics Pharmaceuticals Inc

1.21 81.1 Mil
Healthcare